Bayer partner seeks approval for Darolutamide plus androgen deprivation therapy for metastatic hormone sensitive prostate cancer Ruchika Sharma8 Jan 2025 12:30 PM ISTOrion's collaboration partner Bayer has submitted an application to the Center of Drug Evaluation (CDE) of China's National Medical Products...
Merck announces Phase 3 trial initiations for 4 investigational candidates from its hematology, oncology pipeline Ruchika Sharma6 Jan 2024 12:30 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced the initiation of pivotal Phase 3 trials for four of its...
Bayer gets USFDA nod for Darolutamide, Docetaxel combo to treat metastatic hormone-sensitive prostate cancer Ruchika Sharma10 Aug 2022 3:00 PM ISTDarolutamide is developed jointly by Bayer and Orion Corporation, a globally operating Finnish pharmaceutical company.
Drugmaker Orion sees inflation hit in H2 after quarterly profit beat Ruchika Sharma17 July 2022 9:00 AM ISTNew Delhi: Finnish drugmaker Orion on Friday reported better-than-expected quarterly earnings helped by strong sales of prostate cancer treatment...
Merck, Orion join hands for Investigational Steroid Synthesis Inhibitor ODM-208 to treat Metastatic Castration-Resistant Prostate Cancer Ruchika Sharma14 July 2022 5:00 PM ISTMerck will make an upfront payment to Orion of USD 290 million, which will be expensed by Merck in the third quarter of 2022 and included in non-GAAP...
Aurobindo arm, Orion expand licensing deal to commercialize biosimilars pipeline in select European markets Ruchika Sharma12 Jan 2022 1:18 PM ISTHyderabad: Aurobindo Pharma Limited (along with its subsidiaries together referred to as "Aurobindo") has announced that its subsidiary CuraTeQ...
